DMK PHARMACEUTICALS CORPORATION Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 3 rows, 3 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-09-15: Reporting owner Versi Ebrahim; Form 4; Security Series E Convertible Preferred Stock; Transaction C Conversion of derivative security.
- 2023-05-25: Reporting owner Versi Ebrahim; Form 4; Security Series E Convertible Preferred Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-05-25: Reporting owner Versi Jannine; Form 4; Security Series E Convertible Preferred Stock; Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-09-15 | Versi Ebrahim Director, Officer (CEO) | 4 | Series E Convertible Preferred Stock Derivative · Indirect · By Versi Group LLC | C Conversion of derivative security | −729 1,212 owned after | $0.00 | 2023-09-19 | |
| 2023-05-25 | Versi Ebrahim Director, Officer (CEO) | 4 | Series E Convertible Preferred Stock Derivative · Indirect · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,941 1,941 owned after | no price filed | 2023-05-30 | |
| 2023-05-25 | Versi Jannine Director | 4 | Series E Convertible Preferred Stock Derivative · Indirect · (m) | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,941 1,941 owned after | no price filed | 2023-05-30 |